Top Story

First-line pembrolizumab superior to ipilimumab for advanced melanoma

First-line pembrolizumab superior to ipilimumab for advanced melanoma
April 19, 2015

Read the Perspective from Suzanne L. Topalian, MD

PHILADELPHIA — Patients with advanced melanoma who received first-line pembrolizumab achieved significantly prolonged OS and PFS compared with patients who received ipilimumab, according to phase 3 study results presented at the American Association for Cancer Research Annual Meeting.

These results represent the first randomized comparison of two FDA-approved immune checkpoint inhibitors for the first-line treatment of advanced melanoma, according to the researchers.

Edward Garon Meeting News CoveragePerspective

PD-L1 expression linked to pembrolizumab activity in advanced NSCLC

April 19, 2015
PHILADELPHIA — Pembrolizumab yielded durable response rates and demonstrated tolerability in previously treated and treatment-naive patients with non–small…
Meeting News Coverage

SLNB used in patients with thin melanomas prior to guidelines

April 18, 2015
NEW YORK — Sentinel lymph node biopsy was used in patients with thin melanomas who did not have high-risk features and who had a very low risk for sentinel lymph…
Meeting News Coverage

HD IL-2 extends OS in malignant melanoma

April 18, 2015
NEW YORK — Patients with metastatic melanoma treated with high-dose interleukin-2 demonstrated improved OS compared with historical reference standards, according…

Oncology Nursing Society to kick off its 40th Annual Congress

April 17, 2015
The Oncology Nursing Society will kick off its 2015 Annual Congress on Wednesday, April 22 in Orlando, Fla., marking its 40th year of providing comprehensive nursing…
More News Headlines »
CME
Hematology Oncology Case Consults

Diagnosis and Management of Hemophilia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case…
More »
Meeting News Coverage Video
VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

April 12, 2015
Robert O. Dillman, MD, vice president of oncology at NeoStem Inc., provides an overview of a phase 3 trial evaluating…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan
morganatic-roan